C tc dng h tr cp m, thu nh l chn lng, h tr dng trng da, h tr ci thin ln da khng u mu

The maintenance phase challenge What happens when you stop: Appetite returns (gradually over weeks) Need to rely on habits built during weight loss Risk of regaining weight if not careful Success factors: How long you maintained at goal weight while on peptides Habits built during weight loss phase Continued protein intake and training Realistic expectations (some people maintain perfectly, others regain some) Tapering off GLP-1s Don't quit cold turkey: Gradually reduce dose over 4-8 weeks Example: 2.4mg 1.7mg 1mg 0.5mg 0.25mg stop This allows appetite to return gradually Gives you time to adjust habits While tapering: Monitor weight weekly If starting to regain, slow taper Maintain protein intake religiously Keep training consistent Long-term maintenance options Option 1: Cruise dose Stay on low dose GLP-1 indefinitely (0.25-0.5mg weekly) Maintains some appetite suppression Prevents regain Safer long-term than high doses Option 2: Cycle on/off 3-4 months on, 1-2 months off Return to peptides if weight creeps up 5+ pounds Allows body breaks from medication Option 3: Switch to sustainable peptides Transition from GLP-1s to CJC-1295/Ipamorelin Maintains metabolic benefits Supports muscle and recovery No appetite suppression (must rely on habits) Learn how to structure long-term protocols in our peptide cycle planning guide

Cagrilintide (an amylin analog) combined with semaglutide as CagriSema is in late-stage trials for obesity
grazing, nighttime eating, emotional eating triggers), current physical activity levels and exercise habits, sleep duration and quality, stress management strategies, alcohol consumption frequency and quantity, smoking status, and psychosocial factors affecting weight including work stress, family dynamics, and social support systems
The medication is packaged and labeled in compliance with pharmacy regulations before dispensing